Identifying Atopic Dermatitis Patients at Risk for Developing Conjunctivitis During Dupilumab Treatment

UMC Utrecht

Status: Enrolling

Conditions: Atopic Dermatitis

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT04276623

18/537

Details and patient eligibility

About

Study on ophthalmological comorbidities and the underlying pathomechanisms of conjunctivitis during dupilumab treatment in atopic dermatitis (AD) patients. Patients participate in the Bioday Registry.

Enrollment: 150 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients with atopic dermatitis indicated for dupilumab, without current use of oral immunosuppressive treatment .

Exclusion criteria

• Treatment with oral or ocular immunosuppressive drugs 2 weeks prior to start of dupilumab treatment